Browse ZNF277

Summary
SymbolZNF277
Namezinc finger protein 277
Aliases NRIF4; ZNF277P; zinc finger protein (C2H2 type) 277; zinc finger protein 277 pseudogene; NRIF4P; nuclear rec ......
Chromosomal Location7q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain -
Function

May be involved in transcriptional regulation.

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0006979 response to oxidative stress
GO:0007568 aging
GO:0007569 cell aging
GO:0010035 response to inorganic substance
GO:0034599 cellular response to oxidative stress
GO:0034614 cellular response to reactive oxygen species
GO:0042542 response to hydrogen peroxide
GO:0070301 cellular response to hydrogen peroxide
GO:0090342 regulation of cell aging
GO:0090398 cellular senescence
GO:2000772 regulation of cellular senescence
Molecular Function GO:0000979 RNA polymerase II core promoter sequence-specific DNA binding
GO:0001046 core promoter sequence-specific DNA binding
GO:0001047 core promoter binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolZNF277
Namezinc finger protein 277
Aliases NRIF4; ZNF277P; zinc finger protein (C2H2 type) 277; zinc finger protein 277 pseudogene; NRIF4P; nuclear rec ......
Chromosomal Location7q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ZNF277 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolZNF277
Namezinc finger protein 277
Aliases NRIF4; ZNF277P; zinc finger protein (C2H2 type) 277; zinc finger protein 277 pseudogene; NRIF4P; nuclear rec ......
Chromosomal Location7q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ZNF277 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolZNF277
Namezinc finger protein 277
Aliases NRIF4; ZNF277P; zinc finger protein (C2H2 type) 277; zinc finger protein 277 pseudogene; NRIF4P; nuclear rec ......
Chromosomal Location7q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ZNF277 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.5150.0696
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.6120.685
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4460.687
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.7280.0383
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.8480.702
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5810.842
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0150.965
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0430.976
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0490.975
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.050.969
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0820.968
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0860.212
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ZNF277 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolZNF277
Namezinc finger protein 277
Aliases NRIF4; ZNF277P; zinc finger protein (C2H2 type) 277; zinc finger protein 277 pseudogene; NRIF4P; nuclear rec ......
Chromosomal Location7q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ZNF277. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolZNF277
Namezinc finger protein 277
Aliases NRIF4; ZNF277P; zinc finger protein (C2H2 type) 277; zinc finger protein 277 pseudogene; NRIF4P; nuclear rec ......
Chromosomal Location7q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ZNF277. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ZNF277.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolZNF277
Namezinc finger protein 277
Aliases NRIF4; ZNF277P; zinc finger protein (C2H2 type) 277; zinc finger protein 277 pseudogene; NRIF4P; nuclear rec ......
Chromosomal Location7q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ZNF277. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolZNF277
Namezinc finger protein 277
Aliases NRIF4; ZNF277P; zinc finger protein (C2H2 type) 277; zinc finger protein 277 pseudogene; NRIF4P; nuclear rec ......
Chromosomal Location7q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ZNF277 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolZNF277
Namezinc finger protein 277
Aliases NRIF4; ZNF277P; zinc finger protein (C2H2 type) 277; zinc finger protein 277 pseudogene; NRIF4P; nuclear rec ......
Chromosomal Location7q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ZNF277 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolZNF277
Namezinc finger protein 277
Aliases NRIF4; ZNF277P; zinc finger protein (C2H2 type) 277; zinc finger protein 277 pseudogene; NRIF4P; nuclear rec ......
Chromosomal Location7q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ZNF277 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.